id	sid	tid	token	lemma	pos
dpc-4472	1	1	dermatology	dermatology	NOUN
dpc-4472	1	2	:	:	PUNCT
dpc-4472	1	3	practical	practical	ADJ
dpc-4472	1	4	and	and	CCONJ
dpc-4472	1	5	conceptual	conceptual	ADJ
dpc-4472	1	6	research	research	NOUN
dpc-4472	1	7	letter	letter	NOUN
dpc-4472	2	1	|	|	ADV
dpc-4472	2	2	dermatol	dermatol	ADJ
dpc-4472	2	3	pract	pract	NOUN
dpc-4472	2	4	concept	concept	NOUN
dpc-4472	2	5	.	.	PUNCT
dpc-4472	3	1	2024;14(4):e2024244	2024;14(4):e2024244	NUM
dpc-4472	3	2	1	1	NUM
dpc-4472	3	3	palmoplantar	palmoplantar	NOUN
dpc-4472	3	4	psoriasis	psoriasis	NOUN
dpc-4472	3	5	resistant	resistant	ADJ
dpc-4472	3	6	to	to	PART
dpc-4472	3	7	adalimumab	adalimumab	NOUN
dpc-4472	3	8	successfully	successfully	ADV
dpc-4472	3	9	treated	treat	VERB
dpc-4472	3	10	with	with	ADP
dpc-4472	3	11	bimekizumab	bimekizumab	PROPN
dpc-4472	3	12	emanuele	emanuele	PROPN
dpc-4472	3	13	trovato1	trovato1	PROPN
dpc-4472	3	14	,	,	PUNCT
dpc-4472	3	15	martina	martina	PROPN
dpc-4472	3	16	dragotto1	dragotto1	PROPN
dpc-4472	3	17	,	,	PUNCT
dpc-4472	3	18	eugenio	eugenio	PROPN
dpc-4472	3	19	capalbo1	capalbo1	PROPN
dpc-4472	3	20	,	,	PUNCT
dpc-4472	3	21	pietro	pietro	PROPN
dpc-4472	3	22	rubegni1	rubegni1	PROPN
dpc-4472	3	23	1	1	NUM
dpc-4472	3	24	unit	unit	NOUN
dpc-4472	3	25	of	of	ADP
dpc-4472	3	26	dermatology	dermatology	NOUN
dpc-4472	3	27	,	,	PUNCT
dpc-4472	3	28	department	department	NOUN
dpc-4472	3	29	of	of	ADP
dpc-4472	3	30	medical	medical	ADJ
dpc-4472	3	31	,	,	PUNCT
dpc-4472	3	32	surgical	surgical	ADJ
dpc-4472	3	33	and	and	CCONJ
dpc-4472	3	34	neurosciences	neuroscience	NOUN
dpc-4472	3	35	,	,	PUNCT
dpc-4472	3	36	university	university	PROPN
dpc-4472	3	37	of	of	ADP
dpc-4472	3	38	siena	siena	PROPN
dpc-4472	3	39	,	,	PUNCT
dpc-4472	3	40	siena	siena	PROPN
dpc-4472	3	41	,	,	PUNCT
dpc-4472	3	42	italy	italy	PROPN
dpc-4472	3	43	key	key	ADJ
dpc-4472	3	44	words	word	NOUN
dpc-4472	3	45	:	:	PUNCT
dpc-4472	3	46	psoriasis	psoriasis	NOUN
dpc-4472	3	47	,	,	PUNCT
dpc-4472	3	48	face	face	NOUN
dpc-4472	3	49	,	,	PUNCT
dpc-4472	3	50	biologics	biologic	NOUN
dpc-4472	3	51	,	,	PUNCT
dpc-4472	3	52	tildrakizumab	tildrakizumab	NOUN
dpc-4472	3	53	citation	citation	NOUN
dpc-4472	3	54	:	:	PUNCT
dpc-4472	3	55	trovato	trovato	PROPN
dpc-4472	3	56	e	e	PROPN
dpc-4472	3	57	,	,	PUNCT
dpc-4472	3	58	dragotto	dragotto	PROPN
dpc-4472	3	59	m	m	PROPN
dpc-4472	3	60	,	,	PUNCT
dpc-4472	3	61	capalbo	capalbo	NOUN
dpc-4472	3	62	e	e	NOUN
dpc-4472	3	63	,	,	PUNCT
dpc-4472	3	64	rubegni	rubegni	NOUN
dpc-4472	3	65	p.	p.	NOUN
dpc-4472	3	66	palmoplantar	palmoplantar	NOUN
dpc-4472	3	67	psoriasis	psoriasis	NOUN
dpc-4472	3	68	resistant	resistant	ADJ
dpc-4472	3	69	to	to	PART
dpc-4472	3	70	adalimumab	adalimumab	NOUN
dpc-4472	3	71	successfully	successfully	ADV
dpc-4472	3	72	treated	treat	VERB
dpc-4472	3	73	with	with	ADP
dpc-4472	3	74	bimekizumab	bimekizumab	NOUN
dpc-4472	3	75	.	.	PUNCT
dpc-4472	4	1	dermatol	dermatol	NOUN
dpc-4472	4	2	pract	pract	PROPN
dpc-4472	4	3	concept	concept	NOUN
dpc-4472	4	4	.	.	PUNCT
dpc-4472	5	1	2024;14(4):e2024244	2024;14(4):e2024244	X
dpc-4472	5	2	.	.	PUNCT
dpc-4472	6	1	doi	doi	PROPN
dpc-4472	6	2	:	:	PUNCT
dpc-4472	6	3	https://doi.org/10.5826/dpc.1404a244	https://doi.org/10.5826/dpc.1404a244	NOUN
dpc-4472	6	4	accepted	accept	VERB
dpc-4472	6	5	:	:	PUNCT
dpc-4472	6	6	may	may	AUX
dpc-4472	6	7	15	15	NUM
dpc-4472	6	8	,	,	PUNCT
dpc-4472	6	9	2024	2024	NUM
dpc-4472	6	10	;	;	PUNCT
dpc-4472	6	11	published	publish	VERB
dpc-4472	6	12	:	:	PUNCT
dpc-4472	6	13	october	october	PROPN
dpc-4472	6	14	2024	2024	NUM
dpc-4472	7	1	copyright	copyright	NOUN
dpc-4472	7	2	:	:	PUNCT
dpc-4472	7	3	©	©	PROPN
dpc-4472	7	4	2024	2024	NUM
dpc-4472	7	5	trovato	trovato	X
dpc-4472	7	6	et	et	PROPN
dpc-4472	7	7	al	al	PROPN
dpc-4472	7	8	.	.	PUNCT
dpc-4472	8	1	this	this	PRON
dpc-4472	8	2	is	be	AUX
dpc-4472	8	3	an	an	DET
dpc-4472	8	4	open	open	ADJ
dpc-4472	8	5	-	-	PUNCT
dpc-4472	8	6	access	access	NOUN
dpc-4472	8	7	article	article	NOUN
dpc-4472	8	8	distributed	distribute	VERB
dpc-4472	8	9	under	under	ADP
dpc-4472	8	10	the	the	DET
dpc-4472	8	11	terms	term	NOUN
dpc-4472	8	12	of	of	ADP
dpc-4472	8	13	the	the	DET
dpc-4472	8	14	creative	creative	ADJ
dpc-4472	8	15	commons	common	NOUN
dpc-4472	8	16	attributionnoncommercial	attributionnoncommercial	ADJ
dpc-4472	8	17	license	license	NOUN
dpc-4472	8	18	(	(	PUNCT
dpc-4472	8	19	by	by	ADP
dpc-4472	8	20	-	-	PUNCT
dpc-4472	8	21	nc-4.0	nc-4.0	NOUN
dpc-4472	8	22	)	)	PUNCT
dpc-4472	8	23	,	,	PUNCT
dpc-4472	8	24	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-4472	8	25	,	,	PUNCT
dpc-4472	8	26	which	which	PRON
dpc-4472	8	27	permits	permit	VERB
dpc-4472	8	28	unrestricted	unrestricted	ADJ
dpc-4472	8	29	noncommercial	noncommercial	ADJ
dpc-4472	8	30	use	use	NOUN
dpc-4472	8	31	,	,	PUNCT
dpc-4472	8	32	distribution	distribution	NOUN
dpc-4472	8	33	,	,	PUNCT
dpc-4472	8	34	and	and	CCONJ
dpc-4472	8	35	reproduction	reproduction	NOUN
dpc-4472	8	36	in	in	ADP
dpc-4472	8	37	any	any	DET
dpc-4472	8	38	medium	medium	NOUN
dpc-4472	8	39	,	,	PUNCT
dpc-4472	8	40	provided	provide	VERB
dpc-4472	8	41	the	the	DET
dpc-4472	8	42	original	original	ADJ
dpc-4472	8	43	authors	author	NOUN
dpc-4472	8	44	and	and	CCONJ
dpc-4472	8	45	source	source	NOUN
dpc-4472	8	46	are	be	AUX
dpc-4472	8	47	credited	credit	VERB
dpc-4472	8	48	.	.	PUNCT
dpc-4472	9	1	funding	funding	NOUN
dpc-4472	9	2	:	:	PUNCT
dpc-4472	9	3	none	none	NOUN
dpc-4472	9	4	.	.	PUNCT
dpc-4472	10	1	competing	compete	VERB
dpc-4472	10	2	interests	interest	NOUN
dpc-4472	10	3	:	:	PUNCT
dpc-4472	10	4	emanuele	emanuele	PROPN
dpc-4472	10	5	trovato	trovato	PROPN
dpc-4472	10	6	has	have	VERB
dpc-4472	10	7	intermittent	intermittent	ADJ
dpc-4472	10	8	project	project	NOUN
dpc-4472	10	9	focused	focus	VERB
dpc-4472	10	10	consulting	consulting	NOUN
dpc-4472	10	11	and/or	and/or	CCONJ
dpc-4472	10	12	advisory	advisory	ADJ
dpc-4472	10	13	relationships	relationship	NOUN
dpc-4472	10	14	or	or	CCONJ
dpc-4472	10	15	/	/	SYM
dpc-4472	10	16	and	and	CCONJ
dpc-4472	10	17	travel	travel	NOUN
dpc-4472	10	18	-	-	PUNCT
dpc-4472	10	19	congress	congress	PROPN
dpc-4472	10	20	support	support	NOUN
dpc-4472	10	21	with	with	ADP
dpc-4472	10	22	eli	eli	PROPN
dpc-4472	10	23	-	-	PUNCT
dpc-4472	10	24	lilly	lilly	PROPN
dpc-4472	10	25	,	,	PUNCT
dpc-4472	10	26	novartis	novartis	PROPN
dpc-4472	10	27	,	,	PUNCT
dpc-4472	10	28	janssen	janssen	NOUN
dpc-4472	10	29	-	-	PUNCT
dpc-4472	10	30	cilag	cilag	PROPN
dpc-4472	10	31	,	,	PUNCT
dpc-4472	10	32	abbvie	abbvie	NOUN
dpc-4472	10	33	,	,	PUNCT
dpc-4472	10	34	almirall	almirall	NOUN
dpc-4472	10	35	without	without	ADP
dpc-4472	10	36	any	any	DET
dpc-4472	10	37	impact	impact	NOUN
dpc-4472	10	38	on	on	ADP
dpc-4472	10	39	the	the	DET
dpc-4472	10	40	present	present	ADJ
dpc-4472	10	41	manuscript	manuscript	NOUN
dpc-4472	10	42	.	.	PUNCT
dpc-4472	11	1	martina	martina	PROPN
dpc-4472	11	2	dragotto	dragotto	PROPN
dpc-4472	11	3	,	,	PUNCT
dpc-4472	11	4	eugenio	eugenio	PROPN
dpc-4472	11	5	capalbo	capalbo	PROPN
dpc-4472	11	6	and	and	CCONJ
dpc-4472	11	7	pietro	pietro	PROPN
dpc-4472	11	8	rubegni	rubegni	NOUN
dpc-4472	11	9	have	have	VERB
dpc-4472	11	10	no	no	DET
dpc-4472	11	11	conflict	conflict	NOUN
dpc-4472	11	12	of	of	ADP
dpc-4472	11	13	interest	interest	NOUN
dpc-4472	11	14	.	.	PUNCT
dpc-4472	12	1	authorship	authorship	NOUN
dpc-4472	12	2	:	:	PUNCT
dpc-4472	12	3	all	all	DET
dpc-4472	12	4	authors	author	NOUN
dpc-4472	12	5	have	have	AUX
dpc-4472	12	6	contributed	contribute	VERB
dpc-4472	12	7	significantly	significantly	ADV
dpc-4472	12	8	to	to	ADP
dpc-4472	12	9	this	this	DET
dpc-4472	12	10	publication	publication	NOUN
dpc-4472	12	11	.	.	PUNCT
dpc-4472	13	1	corresponding	correspond	VERB
dpc-4472	13	2	author	author	NOUN
dpc-4472	13	3	:	:	PUNCT
dpc-4472	13	4	emanuele	emanuele	PROPN
dpc-4472	13	5	trovato	trovato	PROPN
dpc-4472	13	6	,	,	PUNCT
dpc-4472	13	7	md	md	PROPN
dpc-4472	13	8	,	,	PUNCT
dpc-4472	13	9	unit	unit	NOUN
dpc-4472	13	10	of	of	ADP
dpc-4472	13	11	dermatology	dermatology	NOUN
dpc-4472	13	12	,	,	PUNCT
dpc-4472	13	13	department	department	NOUN
dpc-4472	13	14	of	of	ADP
dpc-4472	13	15	medical	medical	ADJ
dpc-4472	13	16	,	,	PUNCT
dpc-4472	13	17	surgical	surgical	ADJ
dpc-4472	13	18	and	and	CCONJ
dpc-4472	13	19	neurosciences	neuroscience	NOUN
dpc-4472	13	20	,	,	PUNCT
dpc-4472	13	21	university	university	PROPN
dpc-4472	13	22	of	of	ADP
dpc-4472	13	23	siena	siena	PROPN
dpc-4472	13	24	,	,	PUNCT
dpc-4472	13	25	siena	siena	PROPN
dpc-4472	13	26	,	,	PUNCT
dpc-4472	13	27	italy	italy	PROPN
dpc-4472	13	28	.	.	PUNCT
dpc-4472	14	1	phone	phone	NOUN
dpc-4472	14	2	:	:	PUNCT
dpc-4472	14	3	+39	+39	PROPN
dpc-4472	14	4	-	-	PUNCT
dpc-4472	14	5	0577	0577	NUM
dpc-4472	14	6	585428	585428	NUM
dpc-4472	14	7	.	.	PUNCT
dpc-4472	15	1	fax	fax	NOUN
dpc-4472	15	2	:	:	PUNCT
dpc-4472	15	3	+39	+39	NUM
dpc-4472	15	4	0577	0577	NUM
dpc-4472	15	5	44238	44238	NUM
dpc-4472	16	1	e	e	NOUN
dpc-4472	16	2	-	-	NOUN
dpc-4472	16	3	mail	mail	NOUN
dpc-4472	16	4	:	:	PUNCT
dpc-4472	16	5	emanuele.trovato@unisi.it	emanuele.trovato@unisi.it	NOUN
dpc-4472	16	6	introduction	introduction	NOUN
dpc-4472	16	7	palmoplantar	palmoplantar	NOUN
dpc-4472	16	8	psoriasis	psoriasis	NOUN
dpc-4472	16	9	(	(	PUNCT
dpc-4472	16	10	ppp	ppp	NOUN
dpc-4472	16	11	)	)	PUNCT
dpc-4472	16	12	can	can	AUX
dpc-4472	16	13	significantly	significantly	ADV
dpc-4472	16	14	impair	impair	VERB
dpc-4472	16	15	a	a	DET
dpc-4472	16	16	patient	patient	NOUN
dpc-4472	16	17	’s	’s	PART
dpc-4472	16	18	quality	quality	NOUN
dpc-4472	16	19	of	of	ADP
dpc-4472	16	20	life	life	NOUN
dpc-4472	16	21	,	,	PUNCT
dpc-4472	16	22	and	and	CCONJ
dpc-4472	16	23	it	it	PRON
dpc-4472	16	24	also	also	ADV
dpc-4472	16	25	tends	tend	VERB
dpc-4472	16	26	to	to	PART
dpc-4472	16	27	be	be	AUX
dpc-4472	16	28	resistant	resistant	ADJ
dpc-4472	16	29	to	to	ADP
dpc-4472	16	30	conventional	conventional	ADJ
dpc-4472	16	31	therapies	therapy	NOUN
dpc-4472	16	32	[	[	X
dpc-4472	16	33	1	1	NUM
dpc-4472	16	34	]	]	PUNCT
dpc-4472	16	35	.	.	PUNCT
dpc-4472	17	1	this	this	DET
dpc-4472	17	2	condition	condition	NOUN
dpc-4472	17	3	is	be	AUX
dpc-4472	17	4	therefore	therefore	ADV
dpc-4472	17	5	often	often	ADV
dpc-4472	17	6	difficult	difficult	ADJ
dpc-4472	17	7	to	to	PART
dpc-4472	17	8	diagnose	diagnose	VERB
dpc-4472	17	9	and	and	CCONJ
dpc-4472	17	10	treat	treat	VERB
dpc-4472	17	11	.	.	PUNCT
dpc-4472	18	1	often	often	ADV
dpc-4472	18	2	a	a	DET
dpc-4472	18	3	misdiagnosis	misdiagnosis	NOUN
dpc-4472	18	4	of	of	ADP
dpc-4472	18	5	allergic	allergic	ADJ
dpc-4472	18	6	contact	contact	NOUN
dpc-4472	18	7	dermatitis	dermatitis	PROPN
dpc-4472	18	8	or	or	CCONJ
dpc-4472	18	9	keratoderma	keratoderma	NOUN
dpc-4472	18	10	leads	lead	VERB
dpc-4472	18	11	the	the	DET
dpc-4472	18	12	patient	patient	NOUN
dpc-4472	18	13	to	to	ADP
dpc-4472	18	14	long	long	ADJ
dpc-4472	18	15	courses	course	NOUN
dpc-4472	18	16	of	of	ADP
dpc-4472	18	17	local	local	ADJ
dpc-4472	18	18	and	and	CCONJ
dpc-4472	18	19	systemic	systemic	ADJ
dpc-4472	18	20	steroid	steroid	NOUN
dpc-4472	18	21	therapy	therapy	NOUN
dpc-4472	18	22	,	,	PUNCT
dpc-4472	18	23	with	with	ADP
dpc-4472	18	24	no	no	DET
dpc-4472	18	25	benefit	benefit	NOUN
dpc-4472	18	26	.	.	PUNCT
dpc-4472	19	1	to	to	ADP
dpc-4472	19	2	date	date	NOUN
dpc-4472	19	3	,	,	PUNCT
dpc-4472	19	4	several	several	ADJ
dpc-4472	19	5	real	real	ADJ
dpc-4472	19	6	-	-	PUNCT
dpc-4472	19	7	life	life	NOUN
dpc-4472	19	8	experiences	experience	NOUN
dpc-4472	19	9	of	of	ADP
dpc-4472	19	10	ppp	ppp	NOUN
dpc-4472	19	11	treated	treat	VERB
dpc-4472	19	12	with	with	ADP
dpc-4472	19	13	biologic	biologic	NOUN
dpc-4472	19	14	and	and	CCONJ
dpc-4472	19	15	systemic	systemic	ADJ
dpc-4472	19	16	drugs	drug	NOUN
dpc-4472	19	17	have	have	AUX
dpc-4472	19	18	been	be	AUX
dpc-4472	19	19	reported	report	VERB
dpc-4472	19	20	.	.	PUNCT
dpc-4472	20	1	however	however	ADV
dpc-4472	20	2	,	,	PUNCT
dpc-4472	20	3	data	datum	NOUN
dpc-4472	20	4	with	with	ADP
dpc-4472	20	5	bimekizumab	bimekizumab	NOUN
dpc-4472	20	6	are	be	AUX
dpc-4472	20	7	still	still	ADV
dpc-4472	20	8	lacking	lack	VERB
dpc-4472	20	9	.	.	PUNCT
dpc-4472	21	1	case	case	NOUN
dpc-4472	21	2	presentation	presentation	NOUN
dpc-4472	21	3	we	we	PRON
dpc-4472	21	4	report	report	VERB
dpc-4472	21	5	the	the	DET
dpc-4472	21	6	case	case	NOUN
dpc-4472	21	7	of	of	ADP
dpc-4472	21	8	a	a	DET
dpc-4472	21	9	68	68	NUM
dpc-4472	21	10	-	-	PUNCT
dpc-4472	21	11	year	year	NOUN
dpc-4472	21	12	-	-	PUNCT
dpc-4472	21	13	old	old	ADJ
dpc-4472	21	14	man	man	NOUN
dpc-4472	21	15	with	with	ADP
dpc-4472	21	16	plantar	plantar	NOUN
dpc-4472	21	17	and	and	CCONJ
dpc-4472	21	18	palmar	palmar	X
dpc-4472	21	19	hyperkeratosis	hyperkeratosis	NOUN
dpc-4472	21	20	that	that	PRON
dpc-4472	21	21	had	have	AUX
dpc-4472	21	22	been	be	AUX
dpc-4472	21	23	present	present	ADJ
dpc-4472	21	24	for	for	ADP
dpc-4472	21	25	about	about	ADV
dpc-4472	21	26	a	a	PRON
dpc-4472	21	27	month	month	NOUN
dpc-4472	21	28	despite	despite	SCONJ
dpc-4472	21	29	therapy	therapy	NOUN
dpc-4472	21	30	with	with	ADP
dpc-4472	21	31	biosimilar	biosimilar	ADJ
dpc-4472	21	32	adalimumab	adalimumab	NOUN
dpc-4472	21	33	started	start	VERB
dpc-4472	21	34	in	in	ADP
dpc-4472	21	35	2021	2021	NUM
dpc-4472	21	36	.	.	PUNCT
dpc-4472	22	1	the	the	DET
dpc-4472	22	2	patient	patient	NOUN
dpc-4472	22	3	has	have	VERB
dpc-4472	22	4	a	a	DET
dpc-4472	22	5	history	history	NOUN
dpc-4472	22	6	of	of	ADP
dpc-4472	22	7	diabetes	diabetes	NOUN
dpc-4472	22	8	mellitus	mellitus	NOUN
dpc-4472	22	9	,	,	PUNCT
dpc-4472	22	10	hypercholesterolemia	hypercholesterolemia	NOUN
dpc-4472	22	11	,	,	PUNCT
dpc-4472	22	12	and	and	CCONJ
dpc-4472	22	13	arterial	arterial	ADJ
dpc-4472	22	14	hypertension	hypertension	NOUN
dpc-4472	22	15	.	.	PUNCT
dpc-4472	23	1	psoriasis	psoriasis	NOUN
dpc-4472	23	2	was	be	AUX
dpc-4472	23	3	diagnosed	diagnose	VERB
dpc-4472	23	4	about	about	ADP
dpc-4472	23	5	20	20	NUM
dpc-4472	23	6	years	year	NOUN
dpc-4472	23	7	earlier	early	ADV
dpc-4472	23	8	,	,	PUNCT
dpc-4472	23	9	and	and	CCONJ
dpc-4472	23	10	he	he	PRON
dpc-4472	23	11	had	have	AUX
dpc-4472	23	12	already	already	ADV
dpc-4472	23	13	been	be	AUX
dpc-4472	23	14	treated	treat	VERB
dpc-4472	23	15	with	with	ADP
dpc-4472	23	16	cyclosporine	cyclosporine	NOUN
dpc-4472	23	17	and	and	CCONJ
dpc-4472	23	18	acitretin	acitretin	NOUN
dpc-4472	23	19	.	.	PUNCT
dpc-4472	24	1	in	in	ADP
dpc-4472	24	2	addition	addition	NOUN
dpc-4472	24	3	,	,	PUNCT
dpc-4472	24	4	the	the	DET
dpc-4472	24	5	patient	patient	NOUN
dpc-4472	24	6	was	be	AUX
dpc-4472	24	7	already	already	ADV
dpc-4472	24	8	applying	apply	VERB
dpc-4472	24	9	local	local	ADJ
dpc-4472	24	10	therapy	therapy	NOUN
dpc-4472	24	11	with	with	ADP
dpc-4472	24	12	10	10	NUM
dpc-4472	24	13	%	%	NOUN
dpc-4472	24	14	salicylic	salicylic	ADJ
dpc-4472	24	15	acid	acid	NOUN
dpc-4472	24	16	in	in	ADP
dpc-4472	24	17	occlusion	occlusion	NOUN
dpc-4472	24	18	,	,	PUNCT
dpc-4472	24	19	without	without	ADP
dpc-4472	24	20	benefit	benefit	NOUN
dpc-4472	24	21	.	.	PUNCT
dpc-4472	25	1	the	the	DET
dpc-4472	25	2	patient	patient	NOUN
dpc-4472	25	3	was	be	AUX
dpc-4472	25	4	very	very	ADV
dpc-4472	25	5	concerned	concerned	ADJ
dpc-4472	25	6	about	about	ADP
dpc-4472	25	7	the	the	DET
dpc-4472	25	8	worsening	worsening	NOUN
dpc-4472	25	9	of	of	ADP
dpc-4472	25	10	his	his	PRON
dpc-4472	25	11	condition	condition	NOUN
dpc-4472	25	12	despite	despite	SCONJ
dpc-4472	25	13	therapy	therapy	NOUN
dpc-4472	25	14	with	with	ADP
dpc-4472	25	15	adalimumab	adalimumab	NOUN
dpc-4472	25	16	and	and	CCONJ
dpc-4472	25	17	frustrated	frustrate	VERB
dpc-4472	25	18	about	about	ADP
dpc-4472	25	19	the	the	DET
dpc-4472	25	20	invalidation	invalidation	NOUN
dpc-4472	25	21	of	of	ADP
dpc-4472	25	22	his	his	PRON
dpc-4472	25	23	daily	daily	ADJ
dpc-4472	25	24	activities	activity	NOUN
dpc-4472	25	25	.	.	PUNCT
dpc-4472	26	1	on	on	ADP
dpc-4472	26	2	dermatological	dermatological	ADJ
dpc-4472	26	3	examination	examination	NOUN
dpc-4472	26	4	,	,	PUNCT
dpc-4472	26	5	the	the	DET
dpc-4472	26	6	patient	patient	NOUN
dpc-4472	26	7	had	have	VERB
dpc-4472	26	8	significant	significant	ADJ
dpc-4472	26	9	palmar	palmar	NOUN
dpc-4472	26	10	and	and	CCONJ
dpc-4472	26	11	plantar	plantar	NOUN
dpc-4472	26	12	hyperkeratosis	hyperkeratosis	NOUN
dpc-4472	26	13	,	,	PUNCT
dpc-4472	26	14	nail	nail	NOUN
dpc-4472	26	15	involvement	involvement	NOUN
dpc-4472	26	16	with	with	ADP
dpc-4472	26	17	the	the	DET
dpc-4472	26	18	presence	presence	NOUN
dpc-4472	26	19	of	of	ADP
dpc-4472	26	20	distal	distal	ADJ
dpc-4472	26	21	subungual	subungual	ADJ
dpc-4472	26	22	hyperkeratosis	hyperkeratosis	NOUN
dpc-4472	26	23	,	,	PUNCT
dpc-4472	26	24	pitting	pitting	NOUN
dpc-4472	26	25	,	,	PUNCT
dpc-4472	26	26	and	and	CCONJ
dpc-4472	26	27	splinter	splinter	VERB
dpc-4472	26	28	hemorrhages	hemorrhage	NOUN
dpc-4472	26	29	(	(	PUNCT
dpc-4472	26	30	psoriasis	psoriasis	NOUN
dpc-4472	26	31	area	area	NOUN
dpc-4472	26	32	and	and	CCONJ
dpc-4472	26	33	severity	severity	NOUN
dpc-4472	26	34	index	index	NOUN
dpc-4472	26	35	[	[	X
dpc-4472	26	36	pasi	pasi	NOUN
dpc-4472	26	37	]	]	X
dpc-4472	26	38	9	9	NUM
dpc-4472	26	39	;	;	PUNCT
dpc-4472	26	40	moderate	moderate	ADJ
dpc-4472	26	41	pp	pp	PROPN
dpc-4472	26	42	-	-	PUNCT
dpc-4472	26	43	pga	pga	NOUN
dpc-4472	26	44	;	;	PUNCT
dpc-4472	26	45	nail	nail	NOUN
dpc-4472	26	46	psoriasis	psoriasis	NOUN
dpc-4472	26	47	severity	severity	NOUN
dpc-4472	26	48	index	index	NOUN
dpc-4472	26	49	[	[	X
dpc-4472	26	50	napsi	napsi	NOUN
dpc-4472	26	51	]	]	X
dpc-4472	26	52	85	85	NUM
dpc-4472	26	53	;	;	PUNCT
dpc-4472	26	54	dermatology	dermatology	NOUN
dpc-4472	26	55	life	life	NOUN
dpc-4472	26	56	quality	quality	NOUN
dpc-4472	26	57	index	index	NOUN
dpc-4472	27	1	[	[	X
dpc-4472	27	2	dlqi	dlqi	X
dpc-4472	27	3	]	]	X
dpc-4472	27	4	24	24	NUM
dpc-4472	27	5	)	)	PUNCT
dpc-4472	27	6	(	(	PUNCT
dpc-4472	27	7	figure	figure	NOUN
dpc-4472	27	8	1	1	NUM
dpc-4472	27	9	)	)	PUNCT
dpc-4472	27	10	.	.	PUNCT
dpc-4472	28	1	the	the	DET
dpc-4472	28	2	patient	patient	NOUN
dpc-4472	28	3	reported	report	VERB
dpc-4472	28	4	intense	intense	ADJ
dpc-4472	28	5	associated	associated	ADJ
dpc-4472	28	6	painful	painful	ADJ
dpc-4472	28	7	and	and	CCONJ
dpc-4472	28	8	itchy	itchy	ADJ
dpc-4472	28	9	symptoms	symptom	NOUN
dpc-4472	28	10	.	.	PUNCT
dpc-4472	29	1	a	a	DET
dpc-4472	29	2	microscopic	microscopic	ADJ
dpc-4472	29	3	examination	examination	NOUN
dpc-4472	29	4	ruled	rule	VERB
dpc-4472	29	5	out	out	ADP
dpc-4472	29	6	possible	possible	ADJ
dpc-4472	29	7	concomitant	concomitant	ADJ
dpc-4472	29	8	mycosis	mycosis	NOUN
dpc-4472	29	9	.	.	PUNCT
dpc-4472	30	1	in	in	ADP
dpc-4472	30	2	agreement	agreement	NOUN
dpc-4472	30	3	with	with	ADP
dpc-4472	30	4	the	the	DET
dpc-4472	30	5	patient	patient	NOUN
dpc-4472	30	6	,	,	PUNCT
dpc-4472	30	7	we	we	PRON
dpc-4472	30	8	started	start	VERB
dpc-4472	30	9	therapy	therapy	NOUN
dpc-4472	30	10	with	with	ADP
dpc-4472	30	11	bimekizumab	bimekizumab	NOUN
dpc-4472	30	12	320	320	NUM
dpc-4472	30	13	mg	mg	NOUN
dpc-4472	30	14	according	accord	VERB
dpc-4472	30	15	to	to	ADP
dpc-4472	30	16	the	the	DET
dpc-4472	30	17	induction	induction	NOUN
dpc-4472	30	18	and	and	CCONJ
dpc-4472	30	19	maintenance	maintenance	NOUN
dpc-4472	30	20	dosage	dosage	NOUN
dpc-4472	30	21	2	2	NUM
dpc-4472	30	22	research	research	NOUN
dpc-4472	30	23	letter	letter	NOUN
dpc-4472	30	24	|	|	ADV
dpc-4472	30	25	dermatol	dermatol	ADJ
dpc-4472	30	26	pract	pract	NOUN
dpc-4472	30	27	concept	concept	NOUN
dpc-4472	30	28	.	.	PUNCT
dpc-4472	31	1	2024;14(4):e2024244	2024;14(4):e2024244	NUM
dpc-4472	31	2	schedule	schedule	NOUN
dpc-4472	31	3	.	.	PUNCT
dpc-4472	32	1	the	the	DET
dpc-4472	32	2	patient	patient	NOUN
dpc-4472	32	3	was	be	AUX
dpc-4472	32	4	prescribed	prescribe	VERB
dpc-4472	32	5	topical	topical	ADJ
dpc-4472	32	6	emollients	emollient	NOUN
dpc-4472	32	7	to	to	PART
dpc-4472	32	8	reduce	reduce	VERB
dpc-4472	32	9	painful	painful	ADJ
dpc-4472	32	10	symptoms	symptom	NOUN
dpc-4472	32	11	.	.	PUNCT
dpc-4472	33	1	eight	eight	NUM
dpc-4472	33	2	weeks	week	NOUN
dpc-4472	33	3	later	later	ADV
dpc-4472	33	4	,	,	PUNCT
dpc-4472	33	5	we	we	PRON
dpc-4472	33	6	noted	note	VERB
dpc-4472	33	7	a	a	DET
dpc-4472	33	8	marked	mark	VERB
dpc-4472	33	9	improvement	improvement	NOUN
dpc-4472	33	10	with	with	ADP
dpc-4472	33	11	almost	almost	ADV
dpc-4472	33	12	complete	complete	ADJ
dpc-4472	33	13	resolution	resolution	NOUN
dpc-4472	33	14	of	of	ADP
dpc-4472	33	15	skin	skin	NOUN
dpc-4472	33	16	manifestations	manifestation	NOUN
dpc-4472	33	17	,	,	PUNCT
dpc-4472	33	18	with	with	ADP
dpc-4472	33	19	persistence	persistence	NOUN
dpc-4472	33	20	of	of	ADP
dpc-4472	33	21	mild	mild	ADJ
dpc-4472	33	22	hyperkeratosis	hyperkeratosis	NOUN
dpc-4472	33	23	on	on	ADP
dpc-4472	33	24	the	the	DET
dpc-4472	33	25	right	right	ADJ
dpc-4472	33	26	foot	foot	NOUN
dpc-4472	33	27	and	and	CCONJ
dpc-4472	33	28	the	the	DET
dpc-4472	33	29	left	left	ADJ
dpc-4472	33	30	palm	palm	NOUN
dpc-4472	33	31	(	(	PUNCT
dpc-4472	33	32	figure	figure	NOUN
dpc-4472	33	33	2	2	NUM
dpc-4472	33	34	)	)	PUNCT
dpc-4472	33	35	.	.	PUNCT
dpc-4472	34	1	given	give	VERB
dpc-4472	34	2	the	the	DET
dpc-4472	34	3	short	short	ADJ
dpc-4472	34	4	follow	follow	NOUN
dpc-4472	34	5	-	-	PUNCT
dpc-4472	34	6	up	up	NOUN
dpc-4472	34	7	,	,	PUNCT
dpc-4472	34	8	it	it	PRON
dpc-4472	34	9	was	be	AUX
dpc-4472	34	10	possible	possible	ADJ
dpc-4472	34	11	to	to	PART
dpc-4472	34	12	show	show	VERB
dpc-4472	34	13	just	just	ADV
dpc-4472	34	14	a	a	DET
dpc-4472	34	15	mild	mild	ADJ
dpc-4472	34	16	improvement	improvement	NOUN
dpc-4472	34	17	on	on	ADP
dpc-4472	34	18	nails	nail	NOUN
dpc-4472	34	19	(	(	PUNCT
dpc-4472	34	20	pasi	pasi	NOUN
dpc-4472	34	21	2	2	NUM
dpc-4472	34	22	;	;	PUNCT
dpc-4472	34	23	mild	mild	ADJ
dpc-4472	34	24	pp	pp	ADJ
dpc-4472	34	25	-	-	PUNCT
dpc-4472	34	26	pga	pga	NOUN
dpc-4472	34	27	;	;	PUNCT
dpc-4472	34	28	napsi	napsi	NOUN
dpc-4472	34	29	68	68	NUM
dpc-4472	34	30	;	;	PUNCT
dpc-4472	34	31	dlqi	dlqi	PROPN
dpc-4472	34	32	2	2	NUM
dpc-4472	34	33	)	)	PUNCT
dpc-4472	34	34	.	.	PUNCT
dpc-4472	35	1	the	the	DET
dpc-4472	35	2	patient	patient	NOUN
dpc-4472	35	3	also	also	ADV
dpc-4472	35	4	reported	report	VERB
dpc-4472	35	5	that	that	SCONJ
dpc-4472	35	6	he	he	PRON
dpc-4472	35	7	had	have	AUX
dpc-4472	35	8	not	not	PART
dpc-4472	35	9	applied	apply	VERB
dpc-4472	35	10	local	local	ADJ
dpc-4472	35	11	emollients	emollient	NOUN
dpc-4472	35	12	and	and	CCONJ
dpc-4472	35	13	that	that	SCONJ
dpc-4472	35	14	he	he	PRON
dpc-4472	35	15	had	have	AUX
dpc-4472	35	16	already	already	ADV
dpc-4472	35	17	noticed	notice	VERB
dpc-4472	35	18	a	a	DET
dpc-4472	35	19	progressive	progressive	ADJ
dpc-4472	35	20	clinical	clinical	ADJ
dpc-4472	35	21	improvement	improvement	NOUN
dpc-4472	35	22	in	in	ADP
dpc-4472	35	23	the	the	DET
dpc-4472	35	24	first	first	ADJ
dpc-4472	35	25	two	two	NUM
dpc-4472	35	26	weeks	week	NOUN
dpc-4472	35	27	.	.	PUNCT
dpc-4472	36	1	the	the	DET
dpc-4472	36	2	patient	patient	NOUN
dpc-4472	36	3	is	be	AUX
dpc-4472	36	4	still	still	ADV
dpc-4472	36	5	in	in	ADP
dpc-4472	36	6	therapy	therapy	NOUN
dpc-4472	36	7	with	with	ADP
dpc-4472	36	8	complete	complete	ADJ
dpc-4472	36	9	resolution	resolution	NOUN
dpc-4472	36	10	at	at	ADP
dpc-4472	36	11	last	last	ADJ
dpc-4472	36	12	follow	follow	NOUN
dpc-4472	36	13	-	-	PUNCT
dpc-4472	36	14	up	up	ADP
dpc-4472	36	15	visit	visit	NOUN
dpc-4472	36	16	.	.	PUNCT
dpc-4472	37	1	conclusion	conclusion	NOUN
dpc-4472	37	2	bimekizumab	bimekizumab	PROPN
dpc-4472	37	3	is	be	AUX
dpc-4472	37	4	a	a	DET
dpc-4472	37	5	humanized	humanize	VERB
dpc-4472	37	6	igg1	igg1	NOUN
dpc-4472	37	7	monoclonal	monoclonal	NOUN
dpc-4472	37	8	antibody	antibody	NOUN
dpc-4472	37	9	directed	direct	VERB
dpc-4472	37	10	against	against	ADP
dpc-4472	37	11	il-17a	il-17a	PROPN
dpc-4472	37	12	and	and	CCONJ
dpc-4472	37	13	il-17f	il-17f	PROPN
dpc-4472	37	14	.	.	PROPN
dpc-4472	38	1	data	datum	NOUN
dpc-4472	38	2	from	from	ADP
dpc-4472	38	3	phase	phase	NOUN
dpc-4472	38	4	iii	iii	NUM
dpc-4472	38	5	clinical	clinical	ADJ
dpc-4472	38	6	trials	trial	NOUN
dpc-4472	38	7	evaluated	evaluate	VERB
dpc-4472	38	8	and	and	CCONJ
dpc-4472	38	9	assessed	assess	VERB
dpc-4472	38	10	its	its	PRON
dpc-4472	38	11	safety	safety	NOUN
dpc-4472	38	12	and	and	CCONJ
dpc-4472	38	13	effectiveness	effectiveness	NOUN
dpc-4472	38	14	in	in	ADP
dpc-4472	38	15	moderate	moderate	ADJ
dpc-4472	38	16	-	-	PUNCT
dpc-4472	38	17	to	to	ADP
dpc-4472	38	18	-	-	PUNCT
dpc-4472	38	19	severe	severe	ADJ
dpc-4472	38	20	psoriasis	psoriasis	NOUN
dpc-4472	38	21	.	.	PUNCT
dpc-4472	39	1	real	real	ADJ
dpc-4472	39	2	-	-	PUNCT
dpc-4472	39	3	life	life	NOUN
dpc-4472	39	4	data	datum	NOUN
dpc-4472	39	5	on	on	ADP
dpc-4472	39	6	patients	patient	NOUN
dpc-4472	39	7	with	with	ADP
dpc-4472	39	8	psoriasis	psoriasis	NOUN
dpc-4472	39	9	in	in	ADP
dpc-4472	39	10	particular	particular	ADJ
dpc-4472	39	11	sites	site	NOUN
dpc-4472	39	12	or	or	CCONJ
dpc-4472	39	13	severe	severe	ADJ
dpc-4472	39	14	forms	form	NOUN
dpc-4472	39	15	treated	treat	VERB
dpc-4472	39	16	with	with	ADP
dpc-4472	39	17	bimekizumab	bimekizumab	NOUN
dpc-4472	39	18	are	be	AUX
dpc-4472	39	19	reported	report	VERB
dpc-4472	39	20	in	in	ADP
dpc-4472	39	21	the	the	DET
dpc-4472	39	22	literature	literature	NOUN
dpc-4472	39	23	[	[	X
dpc-4472	39	24	2	2	NUM
dpc-4472	39	25	-	-	SYM
dpc-4472	39	26	6	6	NUM
dpc-4472	39	27	]	]	PUNCT
dpc-4472	39	28	.	.	PUNCT
dpc-4472	40	1	within	within	ADP
dpc-4472	40	2	this	this	DET
dpc-4472	40	3	cohort	cohort	NOUN
dpc-4472	40	4	,	,	PUNCT
dpc-4472	40	5	patients	patient	NOUN
dpc-4472	40	6	with	with	ADP
dpc-4472	40	7	psoriasis	psoriasis	NOUN
dpc-4472	40	8	at	at	ADP
dpc-4472	40	9	particular	particular	ADJ
dpc-4472	40	10	sites	site	NOUN
dpc-4472	40	11	were	be	AUX
dpc-4472	40	12	also	also	ADV
dpc-4472	40	13	involved	involve	VERB
dpc-4472	40	14	,	,	PUNCT
dpc-4472	40	15	although	although	SCONJ
dpc-4472	40	16	post	post	ADJ
dpc-4472	40	17	-	-	ADJ
dpc-4472	40	18	hoc	hoc	ADJ
dpc-4472	40	19	analyses	analysis	NOUN
dpc-4472	40	20	only	only	ADV
dpc-4472	40	21	on	on	ADP
dpc-4472	40	22	these	these	DET
dpc-4472	40	23	patients	patient	NOUN
dpc-4472	40	24	were	be	AUX
dpc-4472	40	25	not	not	PART
dpc-4472	40	26	performed	perform	VERB
dpc-4472	40	27	.	.	PUNCT
dpc-4472	41	1	in	in	ADP
dpc-4472	41	2	our	our	PRON
dpc-4472	41	3	case	case	NOUN
dpc-4472	41	4	,	,	PUNCT
dpc-4472	41	5	it	it	PRON
dpc-4472	41	6	is	be	AUX
dpc-4472	41	7	interesting	interesting	ADJ
dpc-4472	41	8	to	to	PART
dpc-4472	41	9	emphasize	emphasize	VERB
dpc-4472	41	10	the	the	DET
dpc-4472	41	11	rapidity	rapidity	NOUN
dpc-4472	41	12	with	with	ADP
dpc-4472	41	13	which	which	PRON
dpc-4472	41	14	the	the	DET
dpc-4472	41	15	response	response	NOUN
dpc-4472	41	16	was	be	AUX
dpc-4472	41	17	achieved	achieve	VERB
dpc-4472	41	18	,	,	PUNCT
dpc-4472	41	19	resulting	result	VERB
dpc-4472	41	20	in	in	ADP
dpc-4472	41	21	a	a	DET
dpc-4472	41	22	fully	fully	ADV
dpc-4472	41	23	satisfactory	satisfactory	ADJ
dpc-4472	41	24	outcome	outcome	NOUN
dpc-4472	41	25	for	for	ADP
dpc-4472	41	26	both	both	CCONJ
dpc-4472	41	27	patient	patient	ADJ
dpc-4472	41	28	and	and	CCONJ
dpc-4472	41	29	physician	physician	NOUN
dpc-4472	41	30	and	and	CCONJ
dpc-4472	41	31	limiting	limit	VERB
dpc-4472	41	32	the	the	DET
dpc-4472	41	33	use	use	NOUN
dpc-4472	41	34	of	of	ADP
dpc-4472	41	35	local	local	ADJ
dpc-4472	41	36	therapies	therapy	NOUN
dpc-4472	41	37	.	.	PUNCT
dpc-4472	42	1	it	it	PRON
dpc-4472	42	2	is	be	AUX
dpc-4472	42	3	also	also	ADV
dpc-4472	42	4	crucial	crucial	ADJ
dpc-4472	42	5	to	to	PART
dpc-4472	42	6	emphasize	emphasize	VERB
dpc-4472	42	7	the	the	DET
dpc-4472	42	8	impact	impact	NOUN
dpc-4472	42	9	on	on	ADP
dpc-4472	42	10	patient	patient	ADJ
dpc-4472	42	11	quality	quality	NOUN
dpc-4472	42	12	of	of	ADP
dpc-4472	42	13	life	life	NOUN
dpc-4472	42	14	,	,	PUNCT
dpc-4472	42	15	with	with	ADP
dpc-4472	42	16	a	a	DET
dpc-4472	42	17	fairly	fairly	ADV
dpc-4472	42	18	complete	complete	ADJ
dpc-4472	42	19	reduction	reduction	NOUN
dpc-4472	42	20	in	in	ADP
dpc-4472	42	21	dlqi	dlqi	NOUN
dpc-4472	42	22	in	in	ADP
dpc-4472	42	23	eight	eight	NUM
dpc-4472	42	24	weeks	week	NOUN
dpc-4472	42	25	.	.	PUNCT
dpc-4472	43	1	undoubtedly	undoubtedly	ADV
dpc-4472	43	2	,	,	PUNCT
dpc-4472	43	3	further	further	ADJ
dpc-4472	43	4	studies	study	NOUN
dpc-4472	43	5	and	and	CCONJ
dpc-4472	43	6	data	datum	NOUN
dpc-4472	43	7	are	be	AUX
dpc-4472	43	8	needed	need	VERB
dpc-4472	43	9	to	to	PART
dpc-4472	43	10	confirm	confirm	VERB
dpc-4472	43	11	the	the	DET
dpc-4472	43	12	efficacy	efficacy	NOUN
dpc-4472	43	13	and	and	CCONJ
dpc-4472	43	14	safety	safety	NOUN
dpc-4472	43	15	of	of	ADP
dpc-4472	43	16	bimekizumab	bimekizumab	NOUN
dpc-4472	43	17	in	in	ADP
dpc-4472	43	18	real	real	ADJ
dpc-4472	43	19	life	life	NOUN
dpc-4472	43	20	,	,	PUNCT
dpc-4472	43	21	especially	especially	ADV
dpc-4472	43	22	in	in	ADP
dpc-4472	43	23	patients	patient	NOUN
dpc-4472	43	24	with	with	ADP
dpc-4472	43	25	ppp	ppp	PROPN
dpc-4472	43	26	.	.	PUNCT
dpc-4472	44	1	references	reference	NOUN
dpc-4472	44	2	1	1	NUM
dpc-4472	44	3	.	.	PUNCT
dpc-4472	44	4	trovato	trovato	PROPN
dpc-4472	44	5	e	e	PROPN
dpc-4472	44	6	,	,	PUNCT
dpc-4472	44	7	rubegni	rubegni	VERB
dpc-4472	44	8	p	p	NOUN
dpc-4472	44	9	,	,	PUNCT
dpc-4472	44	10	prignano	prignano	PROPN
dpc-4472	44	11	f.	f.	PROPN
dpc-4472	44	12	place	place	NOUN
dpc-4472	44	13	in	in	ADP
dpc-4472	44	14	therapy	therapy	NOUN
dpc-4472	44	15	of	of	ADP
dpc-4472	44	16	anti	anti	NOUN
dpc-4472	44	17	-	-	ADJ
dpc-4472	44	18	il-17	il-17	NUM
dpc-4472	44	19	and	and	CCONJ
dpc-4472	44	20	23	23	NUM
dpc-4472	44	21	in	in	ADP
dpc-4472	44	22	psoriasis	psoriasis	NOUN
dpc-4472	44	23	according	accord	VERB
dpc-4472	44	24	to	to	ADP
dpc-4472	44	25	the	the	DET
dpc-4472	44	26	severity	severity	NOUN
dpc-4472	44	27	of	of	ADP
dpc-4472	44	28	comorbidities	comorbiditie	NOUN
dpc-4472	44	29	:	:	PUNCT
dpc-4472	44	30	a	a	DET
dpc-4472	44	31	focus	focus	NOUN
dpc-4472	44	32	on	on	ADP
dpc-4472	44	33	cardiovascular	cardiovascular	ADJ
dpc-4472	44	34	disease	disease	NOUN
dpc-4472	44	35	and	and	CCONJ
dpc-4472	44	36	metabolic	metabolic	NOUN
dpc-4472	44	37	syndrome	syndrome	NOUN
dpc-4472	44	38	.	.	PUNCT
dpc-4472	45	1	expert	expert	NOUN
dpc-4472	45	2	opin	opin	NOUN
dpc-4472	45	3	biol	biol	NOUN
dpc-4472	45	4	ther	ther	ADV
dpc-4472	45	5	.	.	PUNCT
dpc-4472	46	1	2022	2022	NUM
dpc-4472	46	2	dec;22(12):1443	dec;22(12):1443	NOUN
dpc-4472	46	3	-	-	PUNCT
dpc-4472	46	4	1448	1448	NUM
dpc-4472	46	5	.	.	PUNCT
dpc-4472	47	1	doi	doi	NOUN
dpc-4472	47	2	:	:	PUNCT
dpc-4472	47	3	10.1080/14712598.2022.2093106	10.1080/14712598.2022.2093106	NUM
dpc-4472	47	4	2	2	X
dpc-4472	47	5	.	.	PUNCT
dpc-4472	48	1	valenti	valenti	PROPN
dpc-4472	48	2	m	m	PROPN
dpc-4472	48	3	,	,	PUNCT
dpc-4472	48	4	gargiulo	gargiulo	NOUN
dpc-4472	48	5	l	l	NOUN
dpc-4472	48	6	,	,	PUNCT
dpc-4472	48	7	ibba	ibba	ADJ
dpc-4472	48	8	l	l	NOUN
dpc-4472	48	9	,	,	PUNCT
dpc-4472	48	10	pavia	pavia	VERB
dpc-4472	48	11	g	g	NOUN
dpc-4472	48	12	,	,	PUNCT
dpc-4472	48	13	narcisi	narcisi	ADV
dpc-4472	48	14	a	a	PRON
dpc-4472	48	15	,	,	PUNCT
dpc-4472	48	16	costanzo	costanzo	PROPN
dpc-4472	48	17	a.	a.	PROPN
dpc-4472	48	18	sub	sub	PROPN
dpc-4472	48	19	-	-	ADJ
dpc-4472	48	20	erythrodermic	erythrodermic	ADJ
dpc-4472	48	21	psoriasis	psoriasis	NOUN
dpc-4472	48	22	successfully	successfully	ADV
dpc-4472	48	23	treated	treat	VERB
dpc-4472	48	24	with	with	ADP
dpc-4472	48	25	bimekizumab	bimekizumab	NOUN
dpc-4472	48	26	:	:	PUNCT
dpc-4472	48	27	a	a	DET
dpc-4472	48	28	case	case	NOUN
dpc-4472	48	29	report	report	NOUN
dpc-4472	48	30	.	.	PUNCT
dpc-4472	49	1	dermatol	dermatol	NOUN
dpc-4472	49	2	ther	ther	ADV
dpc-4472	49	3	.	.	PUNCT
dpc-4472	50	1	2022;35(12):e15952	2022;35(12):e15952	NOUN
dpc-4472	50	2	.	.	PUNCT
dpc-4472	51	1	doi:10.1111	doi:10.1111	ADJ
dpc-4472	51	2	/	/	SYM
dpc-4472	51	3	dth.15952	dth.15952	PROPN
dpc-4472	51	4	3	3	NUM
dpc-4472	51	5	.	.	PUNCT
dpc-4472	51	6	megna	megna	PROPN
dpc-4472	51	7	m	m	PROPN
dpc-4472	51	8	,	,	PUNCT
dpc-4472	51	9	picone	picone	PROPN
dpc-4472	51	10	v	v	PROPN
dpc-4472	51	11	,	,	PUNCT
dpc-4472	51	12	ventura	ventura	PROPN
dpc-4472	51	13	v	v	PROPN
dpc-4472	51	14	,	,	PUNCT
dpc-4472	51	15	et	et	PROPN
dpc-4472	51	16	al	al	PROPN
dpc-4472	51	17	.	.	PUNCT
dpc-4472	52	1	a	a	DET
dpc-4472	52	2	case	case	NOUN
dpc-4472	52	3	of	of	ADP
dpc-4472	52	4	scalp	scalp	NOUN
dpc-4472	52	5	psoriasis	psoriasis	NOUN
dpc-4472	52	6	resistant	resistant	ADJ
dpc-4472	52	7	to	to	ADP
dpc-4472	52	8	ixekizumab	ixekizumab	NOUN
dpc-4472	52	9	treated	treat	VERB
dpc-4472	52	10	with	with	ADP
dpc-4472	52	11	bimekizumab	bimekizumab	NOUN
dpc-4472	52	12	.	.	PUNCT
dpc-4472	53	1	jaad	jaad	NOUN
dpc-4472	53	2	case	case	NOUN
dpc-4472	53	3	rep	rep	PROPN
dpc-4472	53	4	.	.	PROPN
dpc-4472	53	5	2023;38:123	2023;38:123	PROPN
dpc-4472	53	6	-	-	SYM
dpc-4472	53	7	126	126	NUM
dpc-4472	53	8	.	.	PUNCT
dpc-4472	53	9	doi:10.1016	doi:10.1016	PROPN
dpc-4472	53	10	/	/	SYM
dpc-4472	53	11	j.jdcr.2023.05.043	j.jdcr.2023.05.043	PROPN
dpc-4472	53	12	figure	figure	NOUN
dpc-4472	53	13	1	1	NUM
dpc-4472	53	14	.	.	PUNCT
dpc-4472	54	1	palmar	palmar	NOUN
dpc-4472	54	2	and	and	CCONJ
dpc-4472	54	3	plantar	plantar	NOUN
dpc-4472	54	4	hyperkeratosis	hyperkeratosis	NOUN
dpc-4472	54	5	,	,	PUNCT
dpc-4472	54	6	nail	nail	NOUN
dpc-4472	54	7	involvement	involvement	NOUN
dpc-4472	54	8	with	with	ADP
dpc-4472	54	9	the	the	DET
dpc-4472	54	10	presence	presence	NOUN
dpc-4472	54	11	of	of	ADP
dpc-4472	54	12	distal	distal	ADJ
dpc-4472	54	13	subungual	subungual	ADJ
dpc-4472	54	14	hyperkeratosis	hyperkeratosis	NOUN
dpc-4472	54	15	,	,	PUNCT
dpc-4472	54	16	pitting	pitting	NOUN
dpc-4472	54	17	,	,	PUNCT
dpc-4472	54	18	and	and	CCONJ
dpc-4472	54	19	splinter	splinter	VERB
dpc-4472	54	20	hemorrhages	hemorrhage	NOUN
dpc-4472	54	21	(	(	PUNCT
dpc-4472	54	22	pasi	pasi	NOUN
dpc-4472	54	23	9	9	NUM
dpc-4472	54	24	;	;	PUNCT
dpc-4472	54	25	moderate	moderate	ADJ
dpc-4472	54	26	pp	pp	PROPN
dpc-4472	54	27	-	-	PUNCT
dpc-4472	54	28	pga	pga	NOUN
dpc-4472	54	29	;	;	PUNCT
dpc-4472	54	30	napsi	napsi	NOUN
dpc-4472	54	31	85	85	NUM
dpc-4472	54	32	)	)	PUNCT
dpc-4472	54	33	.	.	PUNCT
dpc-4472	55	1	figure	figure	NOUN
dpc-4472	55	2	2	2	NUM
dpc-4472	55	3	.	.	PUNCT
dpc-4472	55	4	almost	almost	ADV
dpc-4472	55	5	complete	complete	ADJ
dpc-4472	55	6	resolution	resolution	NOUN
dpc-4472	55	7	of	of	ADP
dpc-4472	55	8	skin	skin	NOUN
dpc-4472	55	9	manifestations	manifestation	NOUN
dpc-4472	55	10	with	with	ADP
dpc-4472	55	11	persistence	persistence	NOUN
dpc-4472	55	12	of	of	ADP
dpc-4472	55	13	mild	mild	ADJ
dpc-4472	55	14	hyperkeratosis	hyperkeratosis	NOUN
dpc-4472	55	15	on	on	ADP
dpc-4472	55	16	the	the	DET
dpc-4472	55	17	right	right	ADJ
dpc-4472	55	18	foot	foot	NOUN
dpc-4472	55	19	and	and	CCONJ
dpc-4472	55	20	the	the	DET
dpc-4472	55	21	left	left	ADJ
dpc-4472	55	22	palm	palm	NOUN
dpc-4472	55	23	(	(	PUNCT
dpc-4472	55	24	pasi	pasi	NOUN
dpc-4472	55	25	2	2	NUM
dpc-4472	55	26	;	;	PUNCT
dpc-4472	55	27	mild	mild	ADJ
dpc-4472	55	28	pp	pp	ADJ
dpc-4472	55	29	-	-	PUNCT
dpc-4472	55	30	pga	pga	NOUN
dpc-4472	55	31	;	;	PUNCT
dpc-4472	55	32	napsi	napsi	NOUN
dpc-4472	55	33	68	68	NUM
dpc-4472	55	34	)	)	PUNCT
dpc-4472	55	35	.	.	PUNCT
dpc-4472	56	1	research	research	NOUN
dpc-4472	56	2	letter	letter	NOUN
dpc-4472	56	3	|	|	ADV
dpc-4472	56	4	dermatol	dermatol	ADJ
dpc-4472	56	5	pract	pract	NOUN
dpc-4472	56	6	concept	concept	NOUN
dpc-4472	56	7	.	.	PUNCT
dpc-4472	57	1	2024;14(4):e2024244	2024;14(4):e2024244	NUM
dpc-4472	57	2	3	3	NUM
dpc-4472	57	3	6	6	NUM
dpc-4472	57	4	.	.	PUNCT
dpc-4472	58	1	gargiulo	gargiulo	PROPN
dpc-4472	58	2	l	l	PROPN
dpc-4472	58	3	,	,	PUNCT
dpc-4472	58	4	narcisi	narcisi	ADV
dpc-4472	58	5	a	a	DET
dpc-4472	58	6	,	,	PUNCT
dpc-4472	58	7	ibba	ibba	ADJ
dpc-4472	58	8	l	l	NOUN
dpc-4472	58	9	,	,	PUNCT
dpc-4472	58	10	et	et	PROPN
dpc-4472	58	11	al	al	PROPN
dpc-4472	58	12	.	.	PROPN
dpc-4472	58	13	effectiveness	effectiveness	NOUN
dpc-4472	58	14	and	and	CCONJ
dpc-4472	58	15	safety	safety	NOUN
dpc-4472	58	16	of	of	ADP
dpc-4472	58	17	bimekizumab	bimekizumab	NOUN
dpc-4472	58	18	for	for	ADP
dpc-4472	58	19	the	the	DET
dpc-4472	58	20	treatment	treatment	NOUN
dpc-4472	58	21	of	of	ADP
dpc-4472	58	22	plaque	plaque	NOUN
dpc-4472	58	23	psoriasis	psoriasis	NOUN
dpc-4472	58	24	:	:	PUNCT
dpc-4472	58	25	a	a	DET
dpc-4472	58	26	real	real	ADJ
dpc-4472	58	27	-	-	PUNCT
dpc-4472	58	28	life	life	NOUN
dpc-4472	58	29	multicenter	multicenter	NOUN
dpc-4472	58	30	study	study	NOUN
dpc-4472	58	31	-	-	PUNCT
dpc-4472	58	32	il	il	PROPN
dpc-4472	58	33	pso	pso	PROPN
dpc-4472	58	34	(	(	PUNCT
dpc-4472	58	35	italian	italian	ADJ
dpc-4472	58	36	landscape	landscape	NOUN
dpc-4472	58	37	psoriasis	psoriasis	NOUN
dpc-4472	58	38	)	)	PUNCT
dpc-4472	58	39	.	.	PUNCT
dpc-4472	59	1	front	front	PROPN
dpc-4472	59	2	med	med	PROPN
dpc-4472	59	3	(	(	PUNCT
dpc-4472	59	4	lausanne	lausanne	PROPN
dpc-4472	59	5	)	)	PUNCT
dpc-4472	59	6	.	.	PUNCT
dpc-4472	60	1	2023	2023	NUM
dpc-4472	60	2	aug	aug	PROPN
dpc-4472	60	3	8;10:1243843	8;10:1243843	PROPN
dpc-4472	60	4	.	.	PUNCT
dpc-4472	61	1	doi	doi	NOUN
dpc-4472	61	2	:	:	PUNCT
dpc-4472	61	3	10.3389	10.3389	NUM
dpc-4472	61	4	/	/	SYM
dpc-4472	61	5	fmed	fmed	ADJ
dpc-4472	61	6	.2023.1243843	.2023.1243843	PROPN
dpc-4472	61	7	.	.	PUNCT
dpc-4472	62	1	4	4	X
dpc-4472	62	2	.	.	PUNCT
dpc-4472	62	3	megna	megna	PROPN
dpc-4472	62	4	m	m	PROPN
dpc-4472	62	5	,	,	PUNCT
dpc-4472	62	6	battista	battista	PROPN
dpc-4472	62	7	t	t	PROPN
dpc-4472	62	8	,	,	PUNCT
dpc-4472	62	9	potestio	potestio	NOUN
dpc-4472	62	10	l	l	NOUN
dpc-4472	62	11	,	,	PUNCT
dpc-4472	62	12	et	et	PROPN
dpc-4472	62	13	al	al	PROPN
dpc-4472	62	14	.	.	PUNCT
dpc-4472	63	1	a	a	DET
dpc-4472	63	2	case	case	NOUN
dpc-4472	63	3	of	of	ADP
dpc-4472	63	4	erythrodermic	erythrodermic	ADJ
dpc-4472	63	5	psoriasis	psoriasis	NOUN
dpc-4472	63	6	rapidly	rapidly	ADV
dpc-4472	63	7	and	and	CCONJ
dpc-4472	63	8	successfully	successfully	ADV
dpc-4472	63	9	treated	treat	VERB
dpc-4472	63	10	with	with	ADP
dpc-4472	63	11	bimekizumab	bimekizumab	NOUN
dpc-4472	63	12	.	.	PUNCT
dpc-4472	64	1	j	j	PROPN
dpc-4472	64	2	cosmet	cosmet	PROPN
dpc-4472	64	3	dermatol	dermatol	NOUN
dpc-4472	64	4	.	.	PUNCT
dpc-4472	65	1	2023;22(3):1146	2023;22(3):1146	NUM
dpc-4472	65	2	-	-	SYM
dpc-4472	65	3	1148	1148	NUM
dpc-4472	65	4	.	.	PUNCT
dpc-4472	66	1	doi:10.1111	doi:10.1111	ADJ
dpc-4472	66	2	/	/	SYM
dpc-4472	66	3	jocd.15543	jocd.15543	ADJ
dpc-4472	66	4	5	5	NUM
dpc-4472	66	5	.	.	PUNCT
dpc-4472	66	6	passeron	passeron	PROPN
dpc-4472	66	7	t	t	PROPN
dpc-4472	66	8	,	,	PUNCT
dpc-4472	66	9	perrot	perrot	PROPN
dpc-4472	66	10	jl	jl	PROPN
dpc-4472	66	11	,	,	PUNCT
dpc-4472	66	12	jullien	jullien	PROPN
dpc-4472	66	13	d	d	PROPN
dpc-4472	66	14	,	,	PUNCT
dpc-4472	66	15	et	et	PROPN
dpc-4472	66	16	al	al	PROPN
dpc-4472	66	17	.	.	PROPN
dpc-4472	66	18	treatment	treatment	NOUN
dpc-4472	66	19	of	of	ADP
dpc-4472	66	20	severe	severe	ADJ
dpc-4472	66	21	palmoplantar	palmoplantar	NOUN
dpc-4472	66	22	pustular	pustular	ADJ
dpc-4472	66	23	psoriasis	psoriasis	NOUN
dpc-4472	66	24	with	with	ADP
dpc-4472	66	25	bimekizumab	bimekizumab	NOUN
dpc-4472	66	26	.	.	PUNCT
dpc-4472	67	1	jama	jama	PROPN
dpc-4472	67	2	dermatol	dermatol	NOUN
dpc-4472	67	3	.	.	PUNCT
dpc-4472	68	1	2023	2023	NUM
dpc-4472	68	2	dec	dec	PROPN
dpc-4472	68	3	6	6	NUM
dpc-4472	68	4	:	:	PUNCT
dpc-4472	68	5	e235051	e235051	NOUN
dpc-4472	68	6	.	.	PUNCT
dpc-4472	69	1	doi	doi	NOUN
dpc-4472	69	2	:	:	PUNCT
dpc-4472	69	3	10.1001	10.1001	NUM
dpc-4472	69	4	/	/	SYM
dpc-4472	69	5	jamadermatol.2023.5051	jamadermatol.2023.5051	PROPN
dpc-4472	69	6	.	.	PUNCT